



2072 38 11 25 11:57

Office of Special Nutrition (HFS-450)  
Center for Food Safety and Applied Nutrition  
U.S. Food and Drug Administration  
200 C Street, S.W.  
Washington, D.C. 20204

December 3, 2004

DEC 22 2004

Re: Maginex™

Ladies and Gentlemen:

This letter notifies the Food and Drug Administration that effective October 1, 2004, our company has begun to market Maginex, a magnesium dietary supplement, formerly distributed by Geist Pharmaceuticals, LLC. The following statements of nutritional support included on the label and in labeling the product:

Clinical research links magnesium with the proper function of:

- Heart and cardiovascular system
- Muscle and bone structure
- Metabolism of naturally produced substances within the body, such as glucose\*

Americans with certain heart and circulatory conditions are at a greater risk for magnesium depletion. The use of particular diuretics, consumption of alcohol and strenuous activity may further deplete the body of magnesium. Symptoms of magnesium depletion may include occasional leg cramping, restlessness, and headaches.\*

The dietary ingredient of the product that is subject to the above statement is:

Magnesium

It is hereby certified that the information in this notification is complete and accurate, and that our company has substantiation that the above statement is truthful and not misleading.

Very truly yours,

Logan Pharmaceuticals

Vincent J. Gilday Jr.  
Vice President Finance and Operations

90448

975 0162 LET 15255